Anti-VEGF Perforation Stent — SCE Medical Oncology MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: D — Peritoneal carcinomatosis with bowel-wall tumour infiltration and a poorly healed prior bowel anastomosis
The cabozantinib risk-management plan identifies carcinomatosis, tumour infiltration of gastrointestinal viscera and complications from prior gastrointestinal surgery, particularly delayed or incomplete healing, as perforation risk factors. Controlled reflux without structural disease is not a listed high-risk state. A fully healed remote cholecystectomy does not carry the same risk. Lactose intolerance does not create inflammatory or infiltrative bowel injury. A remote, uncomplicated appendicectomy is not equivalent to current tumour infiltration or impaired healing.
Reference: CABOMETYX UK summary of product characteristics (Current UK SmPC, accessed July 2026): https://www.medicines.org.uk/emc/product/4331/smpc